糖皮质激素治疗感染相关性肾小球肾炎的疗效——一项随机对照试验
该单中心随机对照试验将52例经活检确诊且血清肌酐大于1.5 mg/dl的感染相关性肾小球肾炎(IRGN)患者随机分入糖皮质激素联合支持治疗组或单纯支持治疗组,随访6个月。6个月时干预组26例中17例(65.4%)与对照组26例中14例(53.8%)达到完全肾脏恢复(比值比1.6;95%置信区间0.5-4.9;P=0.397),差异无统计学意义;干预组12例(46.2%)发生不良事件,对照组2例(7.7%)(P=0.002)。
要点
- 6个月完全肾脏恢复率干预组65.4% vs 对照组53.8%,比值比1.6(95%CI 0.5-4.9;P=0.397),未达统计学显著。
- 不良事件干预组12例(46.2%)vs 对照组2例(7.7%)(P=0.002),糖皮质激素组不良事件风险显著增加。
- 该单中心试验中糖皮质激素未使6个月完全肾脏恢复率出现统计学显著升高。
核心结论
- 在这项单中心试验中,糖皮质激素未使6个月完全肾脏恢复率出现统计学显著升高,且与糖皮质激素使用相关的不良事件风险显著增加。
研究设计与样本
- 随机对照试验,将经活检确诊IRGN且血清肌酐大于1.5 mg/dl的患者随机分入糖皮质激素联合支持治疗组(干预组)或单纯支持治疗组(对照组),随访6个月,主要结局为6个月完全肾脏恢复,并评估糖皮质激素治疗的安全性。
主要发现
- 共52例患者接受随机分组。
- 6个月时干预组26例中17例(65.4%)与对照组26例中14例(53.8%)达到完全肾脏恢复(比值比1.6;95%置信区间0.5-4.9;P=0.397)。
- 任何次要结局均无统计学显著差异。
- 不良事件干预组12例(46.2%)vs 对照组2例(7.7%)(P=0.002)。
局限性
- 原文结论自述为单中心试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Infection-related glomerulonephritis (IRGN) is associated with glomerular immune complex deposition along with complement activation. Steroids may attenuate glomerular injury and thereby improve renal outcomes. METHODS: We randomly assigned patients who had biopsy-proven IRGN and serum creatinine greater than 1.5 mg/dl to receive corticosteroids plus supportive care (intervention arm), or supportive care alone (control arm). Patients were followed up for 6 months. The primary outcome was complete renal recovery at 6 months. Safety of steroid therapy was also assessed. RESULTS: A total of 52 patients underwent randomization. At 6 months, 17 of 26 patients (65.4%) in the intervention arm and 14 of 26 patients (53.8%) in the control arm had complete renal recovery (odds ratio 1.6; 95% confidence interval, 0.5-4.9; P = 0.397). There was no statistically significant difference in any of the secondary outcomes. Adverse events occurred in 12 patients (46.2%) in the intervention arm and 2 patients (7.7%) in the control arm (P = 0.002). CONCLUSION: In this single-center trial, corticosteroids did not result in a statistically significant increase in rates of complete renal recovery at 6 months. There was a significantly increased risk of adverse events associated with the use of corticosteroids.
引用
- Arivazhagan S, Lamech TM, Myvizhiselvi M, et al. Efficacy of Corticosteroids in Infection-Related Glomerulonephritis-A Randomized Controlled Trial. Kidney Int Rep. 2022. PMID: 36217524. doi:10.1016/j.ekir.2022.07.163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。